Healthcare Equipment and Supplies
Company Overview of TYRX, Inc.
TYRX, Inc. designs, develops, and manufactures implantable combination drug+device products focused on infection control for patients in the United States. It offers AIGISRx, an antibacterial envelope for holding a pacemaker or implantable cardioverter-defibrillator to create a stable environment surrounding the device and leads after surgical placement. The company’s AIGISRx antibacterial envelope reduces surgical site infections associated with cardiac implantable electronic devices. It delivers implantable medical-pharmaceutical combination devices for the surgical markets. TYRX, Inc. was formerly known as Advanced Materials Design, LLC. The company was founded in 1998 and is based in Mon...
1 Deer Park Drive
Monmouth Junction, NJ 08852
Founded in 1998
Key Executives for TYRX, Inc.
Vice President of Advanced Products
Vice President of Product Development
Compensation as of Fiscal Year 2014.
TYRX, Inc. Key Developments
TYRX, Inc. Announces First Implantation of AIGISRx R Fully Bioresorbable Antibacterial Envelope
Aug 7 13
TYRX, Inc. announced that the first implantation of its new AIGISRx R Fully Resorbable Antibacterial Envelope has taken place at the Vanderbilt Heart and Vascular Institute in Nashville, TN by Dr. Christopher R. Ellis. The AIGISRx R Antibacterial Envelope received U.S Food and Drug Administration (FDA) clearance on May 20, 2013. The AIGISRx R device is a fully bioresorbable, antibacterial mesh envelope, intended to hold Cardiac Implantable Electronic Devices (CIEDs), such as pacemakers and implantable cardioverter defibrillators (ICDs) securely in place to provide a stable environment when implanted in the body. The AIGISRx R contains the antimicrobial agents rifampin and minocycline, which are released locally into the tissue to help reduce Surgical Site Infections (SSIs) associated with CIED implantation. Multiple studies have shown that patients at high risk for CIED infection who are implanted with the AIGISRx Antibacterial Envelope had 70% to 100% fewer device infections than similar patients who did who did not receive the AIGISRx. Vanderbilt Heart and Vascular Institute recently performed a matched cohort study to compare the incidence of CIED infection in patients receiving a CIED with or without an AIGISRx Antibacterial Envelope. After a minimum of 90days of follow-up, the incidence of CIED infection was significantly lower in the group that received the AIGISRx, compared to those that did not (0.4% vs. 3.0%, OR = 0.13 [0.02-0.95],p=0.04). There were 87% fewer CIED infections in patients who received the AIGISRx, compared to those who did not.
TYRX Receives Fda Clearance for Fully Resorbable AIGISRx R Antibacterial Envelope
Jul 9 13
TYRX, Inc. announced that it has received U.S. Food and Drug Administration (FDA) clearance to market the Fully Resorbable AIGISRx R Antibacterial Envelope for use with pacemakers and implantable cardioverter defibrillators (ICDs). The AIGISRx R Antibacterial Envelope received approval from Health Canada in January 2013. AIGISRx R is a fully bioresorbable, antibacterial mesh envelope, intended to hold CIEDs securely in place in order to provide a stable environment when implanted in the body. Key to its design, AIGISRx R contains the antimicrobial agents rifampin and minocycline, which are released locally into the tissue, to help reduce surgical site infections (SSIs) associated with CIED implantation. Multiple studies have shown that in patients at high-risk for device infection, CIED implantation with the AIGISRx Antibacterial Envelope significantly reduced device infections by 70% - 100%, compared to patients who did not receive the AIGISRx. Patients with SSIs following CIED procedures spend an average of two extra weeks in the hospital, undergo repeat surgical procedures to treat the infection, and cost the facility an average of $72,485. Additionally, such patients experience significant increases in morbidity and mortality, with 1-year mortality rates of 26.5 -35.1%, and 3-year mortality of up to 50%, depending on device type.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|